FDA Recall Roundup: 10 Class II Actions — Compounding Sterility Failures Dominate

Ten Class II recalls posted today, with no Class I actions reported. The largest cluster involves six compounded injectable products from a single South Carolina pharmacy citing sterility assurance failures tied to processing equipment and formulation issues; two additional recalls cover eye drop lines manufactured by K.C. Pharmaceuticals under multiple private-label brands. Rounding out the list are a Cipla oral antibiotic solution pulled for failed impurity specifications and a Janssen biologic recalled for particulate matter.

Six separate compounded injectable lines from this single firm share the same root-cause language around processing equipment and, in two cases, bacteriostatic water formulation. The clustering across multiple product codes over a one-month manufacturing window (July–August 2026) suggests a systemic facility-level sterility control issue rather than isolated batch failures. Prescribers and patients using these compounded erectile-dysfunction and weight-management injectables should confirm lot numbers against the issued BUD dates.

A single manufacturer's sterility deficiency has cascaded across ten-plus private-label retail brands nationwide, affecting two distinct ophthalmic formulations. Given the broad retail footprint (major grocery and pharmacy chains), consumer-facing recall notices should be prioritized.

This recall is geographically limited to Ohio and involves a single lot of a newer biologic indicated for myasthenia gravis; particulate contamination in an IV infusion product warrants immediate clinical staff notification at affected sites.